其它产品项目整合

项目整合的本质是一项集合成方法学、反应工程学与过程分析技术于一体的系统工程。其核心逻辑可以概括为以下几点：源头优选：利用如N-硝胺化学等底层方法学突破，从分子层面颠覆传统高成本、高污染路线。过程强化：依托连续流技术，攻克有机金属试剂应用、光化学反应放大等“不可能”任务，实现高危工艺的本质安全。系统集成：整合“反应-淬灭-分离”全流程，利用微流控与在线分析技术，消除批次间的差异，实现药品制造的连续化与智能化。当前，中间体工艺研发正在经历从“经验驱动”向“数据驱动”的转变。AI辅助路线设计、自动化高通量筛选与连续制造平台的结合，将使得“分子结构与最优工艺路径”之间的映射关系逐渐清晰。未来的竞争优势，将属于那些能够将底层化学创新与先进工程技术进行无缝整合的研发体系。
备注: 根据相关法律法规, 本站点不显示有法律约束管制的产品, 如有遗漏, 请自行鉴别,或提交我们及时更新撤除.
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

其它产品项目整合

Dichlormid CAS Registry Number: 37764-25-3 二氯丙烯胺

CAS Name: 2,2-Dichloro-N,N-di-2-propenylacetamide
Additional Names: N,N-diallyl-2,2-dichloroacetamidePercent Composition: C 46.18%, H 5.33%, Cl 34.07%, N 6.73%, O 7.69%
Literature References: Increases corn tolerance to thiocarbamate and chloroacetanilide herbicides. Field and growth room trials in protection of corn from herbicide injury: F. Y. Chang et al., Can. J. Plant Sci. 52, 707 (1972); eidem, Weed Res. 13, 399 (1973). Effects on uptake and metabolism of EPTC, q.v.: eidem, J. Agric. Food Chem. 22, 245 (1974). Prepn and use in combination with thiocarbamate herbicides: F. M. Pallos et al., US 4021224 (1977 to Stauffer). Synergistic activity with herbicides that affect photosynthesis: C. Fedtke, R. H. Strang, Z. Naturforsch. 45c, 565 (1990). Effects on lipid biosynthesis in maize: I. Cs. Barta, ibid. 46c, 926 (1991); in barley and wild oats: A. Baldwin et al., J. Exp. Bot. 54, 1289 (2003). Environmental tolerances: Fed. Regist. 65, 16143 (2000). Photodegradation study: A. W. Abu-Qare, H. J. Duncan, Chemosphere 46, 1183 (2002).

Cy 5 CAS Registry Number: 146368-15-2 花氰染料CY5

CAS Name: 1-[6-[-(2,5-Dioxo-1-pyrrolidinyl)oxy]-6-oxohexyl]-2-[5-[1-[6-[(2,5-dioxo-1-pyrrolidinyl)oxy]-6-oxohexyl]-1,3-dihydro-3,3-dimethyl-5-sulfo-2H-indol-2-ylidene]-1,3-pentadienyl]-3,3-dimethy...
Literature References: Indocyanine dye with high fluorescence which is easily coupled to proteins. Named CyX.Y where X is the number of bridge carbons and Y represents a unique dye structure. Prepn: A. S. Waggoner et al., DE 3912046; eidem, US 5268486 (1990, 1993 both to Carnegie-Mellon). Use with fiber optic biosensors: L. A. Tempelman et al., Proc. SPIE Int. Soc. Opt. Eng. 2293, 139 (1994); for antibody/antigen detection: R. M. Wadkins et al., ibid. 2676, 148 (1996). Use in resonance energy transfer: P. R. Selvin et al, J. Am. Chem. Soc. 116, 6029 (1994).

Perivine CAS Registry Number: 2673-40-7 派利文碱

CAS Name: 4-Demethyl-3-oxovobasan-17-oic acid methyl ester
Percent Composition: C 70.99%, H 6.55%, N 8.28%, O 14.18%
Literature References: Indole alkaloid from Vinca rosea Linn., Apocynaceae: G. Svoboda, J. Am. Pharm. Assoc. 47, 834 (1958); G. Svoboda et al., ibid. 48, 659 (1959). Structure: Gorman, Sweeny, Tetrahedron Lett. 1964, 3105. Cytotoxicity: D. G. I. Kingston, J. Pharm. Sci. 67, 272 (1978).

Tabernanthine CAS Registry Number: 83-94-3 马山茶碱

CAS Name: 13-Methoxyibogamine
Percent Composition: C 77.38%, H 8.44%, N 9.02%, O 5.15%
Literature References: Indole alkaloid isolated from root of Tabernanthe iboga Baill., Apocynaceae: Delourme-Houdé, Ann. Pharm. Fr. 4, 30 (1946); Dickel et al., J. Am. Chem. Soc. 80, 123 (1958). Also in Tabernaemontana and Stemmadenia spp.; usually found in ibogaine mother liquors: Walls et al., Tetrahedron 2, 173 (1958). Isoln from genus Conopharingia, Apocynaceae: Renner, Prins, US 3008954 (1961 to Geigy). Structure: Bartlett et al., J. Am. Chem. Soc. 80, 126 (1958). Mass spectrum: Biemann, Friedmann-Spiteller, ibid. 83, 4805 (1961). Derivs: Taylor, US 2877229 (1959 to Ciba). Interaction with benzodiazepine receptors: J.-H. Trouvin et al., Eur. J. Pharmacol. 140, 303 (1987).

Ibogaine CAS Registry Number: 83-74-9 伊波加因

CAS Name: 12-Methoxyibogamine
Percent Composition: C 77.38%, H 8.44%, N 9.02%, O 5.15%
Literature References: Indole alkaloid of the iboga group. Isoln from root (1.27%), rootbark (2 to 6%), stems (1.95%) and leaves (0.35%) of the shrub Tabernanthe iboga Baill., Apocynaceae, found in Africa: Dybowski, Landrin, Compt. Rend. 133, 748 (1901); Haller, Heckel, ibid. 850, 1236; from other Apocynaceae: H. Achenbach, B. Raffelsberger, Z. Naturforsch. 35B, 219, 885 (1980); N. Ghorbel et al., J. Nat. Prod. 44, 717 (1981); T. Mulamba et al., ibid. 184; B. Richard et al., ibid. 46, 283 (1983). Purification: Schlittler et al., Helv. Chim. Acta 36, 1341 (1953). Revised extraction procedure: Dickel et al., J. Am. Chem. Soc. 80, 123 (1958). Review of early isolation work: Lebeau, Janot, Traité de Pharmacie Chimique vol. 4 (Masson et Cie., Paris, 1956) pp 2982-2988. Structure: Bartlett et al., J. Am. Chem. Soc. 80, 126 (1958). Mass spectrum: Biemann, Friedmann-Spiteller, ibid. 83, 4805 (1961). Synthesis: Büchi et al., ibid. 88, 3099 (1966); Rosenmund et al., Ber. 108, 1871 (1975). Derivs: Taylor, US 2877229 (1959 to Ciba). Absolute configuration: K. Blàha et al., Tetrahedron Lett. 1972, 2763. Interatomic distances similar to those of serotonin: J. M. Kelley, R. H. Adamson, Pharmacology 10, 28 (1973). NMR spectrum: E. Wenkert et al., Helv. Chim. Acta 59, 2437 (1976). Determn in biological fluids: E. Bertol et al., J. Chromatogr. 117, 239 (1976). Iboga extracts said to be used by African natives while stalking game, to enable them to remain motionless for as long as 2 days while retaining mental alertness. Neuropharmacological studies: Schneider, Sigg, Ann. N.Y. Acad. Sci. 66, 765 (1957); S. Gershon, W. J. Lang, Arch. Int. Pharmacodyn. Ther. 135, 31 (1962). Cardiovascular effects: J. A. Schneider, R. K. Rinehart, ibid. 110, 92 (1957). Serotonergic properties: R. S. Sloviter et al., J. Pharmacol. Exp. Ther. 214, 231 (1980). Experimental use in treatment of heroin addiction: H. S. Lotsof, US 4499096 (1985). Reviews: W. I. Taylor, "The Iboga and Voacanga Alkaloids" in The Alkaloids, Chemistry and Physiology Vol. 8, R. H. F. Manske, Ed. (Academic Press, New York, 1965) p 203-235, idem, ibid. Vol. 11 (1968), pp 79-98.

Nodulisporic acid CAS Registry Number: 163120-03-4 2,4-五二烯酸,5-[(3S,4S,4aR,6aS,12aR,13S,15S,16bS,16cS)-2,3,4,4a,5,6a,7,10,12,12a,13,14,15,16b,16c-六甲酰羟基-3,13-二羟基-4,10,10,12,12,16b,16c-七甲基-15-(1-甲基乙基)-14-氧代-1H-苯[6,7]indeno[1,2-b]吡啶[3',4':4,5]环戊体[1,2-f]吡咯酸[3,2,1-hi]鐲哚-4-基]-2-甲基,(2E,4E)-

CAS Name: (2E,4E)-5-[(3S,4S,4aR,6aS,12aR,13S,15S,16bS,16cS)-2,3,4,4a,5,6,6a,7,10,12,12a,13,14,15,16b,16c-Hexadecahydro-3,13-dihydroxy-4,10,10,12,12,16b,16c-heptamethyl-15-(1-methylethenyl)-14-oxo-...
Literature References: Indole diterpene alkaloid which activates glutamate-gated chloride channels. Isolated from the fungus Nodulisporium sp.; it occurs naturally as the (+)-form. Isoln: A. W. Dombrowski et al., US 5399582 (1995 to Merck Co.); structure determination and insecticidal activity: J. G. Ondeyka et al., J. Am. Chem. Soc. 119, 8809 (1997). Mode of action: M. M. Smith et al., Biochemistry 39, 5543 (2000). Synthetic studies: A. B. Smith, III et al., Org. Lett. 3, 3967, 3971 (2001). Biosynthesis: K. M. Byrne et al., J. Am. Chem. Soc. 124, 7055 (2002). Systemic efficacy against fleas on dogs: W. L. Shoop et al., J. Parasitol. 87, 419 (2001). Review of chemical and biological properties: P. T. Meinke et al., Curr. Top. Med. Chem. 2, 655-674 (2002).

Fantofarone CAS Registry Number: 114432-13-2 泛托法隆

CAS Name: 3,4-Dimethoxy-N-methyl-N-[3-[4-[[2-(1-methylethyl)-1-indolizinyl]sulfonyl]phenoxy]propyl]benzeneethanamine
Additional Names: 2-isopropyl-1-[4-[3-[N-methyl-N-(3,4-dimethoxy-b-phenethyl...
Literature References: Indolizinsulfone calcium channel blocker. Prepn: J. Gubin et al., EP 235111; J. Gubin et al., US 4957925 (1987, 1990 both to Sanofi); eidem, J. Med. Chem. 35, 981 (1992). Binding studies: A. Schmid et al., Mol. Pharmacol. 35, 766 (1989); B. A. Kenny et al., Br. J. Pharmacol. 108, 93 (1993). X-ray structure and electronic properties: V. J. Gibon et al., Eur. J. Med. Chem. 27, 485 (1992). Pharmacokinetics: E. Bellissant et al., Eur. J. Clin. Pharmacol. 41, 329 (1991). Review of pharmacology and clinical evaluations: P. Chatelain et al., Cardiovasc. Drug Rev. 9, 123-146 (1991).

Sodium Phosphate, Dibasic CAS Registry Number: 7558-79-4 磷酸氢二钠

Additional Names: Dibasic sodium phosphate; disodium hydrogen phosphate; disodium orthophosphate; disodium phosphate; DSP; phosphate of soda; secondary sodium phosphate
Percent Composition: H 0...
Literature References: Industrial production: Faith, Keyes Clark's Industrial Chemicals (John Wiley, New York, 4th ed., 1975) pp 746-754. Toxicity of heptahydrate: H. F. Smyth et al., Am. Ind. Hyg. Assoc. J. 30, 470 (1969).

Trichloroisocyanuric Acid CAS Registry Number: 87-90-1 三氯异氰脲酸

CAS Name: 1,3,5-Trichloro-1,3,5-triazine-2,4,6-(1H,3H,5H)-trione
Additional Names: trichloroiminocyanuric acid; TCCATrademarks: Chloreal; Symclosene
Percent Composition: C 15.50%, Cl 45.76%,...
Literature References: Industrially significant bleaching agent and biocide. Prepn: F. D. Chattaway, J. M. Wadmore, J. Chem. Soc. 81, 191 (1902); Hands, Whitt, J. Soc. Chem. Ind. 67, 66 (1948). Structure determn: R. C. Petterson et al., J. Org. Chem. 25, 1595 (1960). Review of synthetic applications as a chlorinating agent or oxidant: U. Tilstam, H. Weinmann, Org. Process Res. Dev. 6, 384-393 (2002); J. C. Barros, Synlett 2005, 2115-2116.

Zanamivir CAS Registry Number: 139110-80-8 扎那米韦

CAS Name: 5-(Acetylamino)-4-[(aminoiminomethyl)amino]-2,6-anhydro-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Additional Names: 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic a...
Literature References: Influenza viral neuraminidase inhibitor; structural analog of the sialic acids, q.v. Prepn: L. M. von Itzstein et al., WO 9116320; eidem, US 5360817 (1991, 1994 both to Biota); M. von Itzstein et al., Carbohydr. Res. 259, 301 (1994). Structure-activity study: eidem et al., Nature 363, 418 (1993). Inhibition of sialidase (neuraminidase) from influenza virus: M. S. Pegg, M. von Itzstein, Biochem. Mol. Biol. Int. 32, 851 (1994). In vitro antiviral activity: J. M. Woods et al., Antimicrob. Agents Chemother. 37, 1473 (1993). HPLC determn in serum: R. J. Stubbs, A. J. Harker, J. Chromatogr. B 670, 279 (1995). Clinical trial in influenza A and B infection: F. G. Hayden et al., N. Engl. J. Med. 337, 874 (1997); in prevention of influenza in healthy adults: A. S. Monto et al., J. Am. Med. Assoc. 282, 31 (1999).